Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 8, 2015, Pages 4457-4463

  Lechartier, Benoit ^a,b   Cole, Stewart T ^a  

^a EPFL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 PIPERAZINO BENZOTHIAZINONE 169; BEDAQUILINE; BENZOTHIAZINE DERIVATIVE; CLOFAZIMINE; MENAQUINONE; OXYGEN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; UNCLASSIFIED DRUG; FARNOQUINONE; PBTZ169; PIPERAZINE DERIVATIVE; QUINOLINE DERIVATIVE; THIAZINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ELECTRON TRANSPORT; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; COMBINATION DRUG THERAPY; DRUG EFFECTS; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANIMALS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; DIARYLQUINOLINES; DRUG THERAPY, COMBINATION; FEMALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PIPERAZINES; THIAZINES; TUBERCULOSIS, MULTIDRUG-RESISTANT; VITAMIN K 2;

EID: 84940204352     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00395-15     Document Type: Article

References (34)

1. World Health Organization. 2013. Global tuberculosis report 2013. World Health Organization, Geneva, Switzerland.
2. Ginsberg A. 2011. The TB Alliance: overcoming challenges to chart the future course of TB drug development. Future Med Chem 3:1247-1252. http://dx.doi.org/10.4155/fmc.11.82.
3. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 2012. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380:986-993. http://dx.doi.org/10.1016/S0140-6736(12)61080-0.
4. Zumla A, Nahid P, Cole ST. 2013. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12:388-404. http://dx.doi.org/10.1038/nrd4001.
5. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 182:684-692. http://dx.doi.org/10.1164/rccm.201001-0077OC.
6. Grosset J, Tyagi S, Almeida D, Converse P, Li S, Ammerman N, Bishai W, Enarson D, Trébucq A. 2013. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 188:608-612. http://dx.doi.org/10.1164/rccm.201304-0753OC.
7. Tyagi S, Ammerman N, Li S, Adamson J, Converse P, Swanson R, Almeida D, Grosset J. 2015. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci U S A 112:869-874. http://dx.doi.org/10.1073/pnas.1416951112.
8. Job C, Yoder L, Jacobson R, Hastings R. 1990. Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal. J Am Acad Dermatol 23:236-241. http://dx.doi.org/10.1016/0190-9622(90)70204-U.
9. Zhang D, Lu Y, Liu K, Liu B, Wang J, Zhang G, Zhang H, Liu Y, Wang B, Zheng M, Fu L, Hou Y, Gong N, Lv Y, Li C, Cooper C, Upton A, Yin D, Ma Z, Huang H. 2012. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis. J Med Chem 55:8409-8417. http://dx.doi.org/10.1021/jm300828h.
10. Yano T, Kassovska-Bratinova S, Teh JS, Winkler J, Sullivan K, Isaacs A, Schechter NM, Rubin H. 2011. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 286:10276-10287. http://dx.doi.org/10.1074/jbc.M110.200501.
11. Makarov V, Manina G, Mikusova K, Mollmann U, Ryabova O, Saint-Joanis B, Dhar N, Pasca MR, Buroni S, Lucarelli AP, Milano A, de Rossi E, Belanova M, Bobovska A, Dianiskova P, Kordulakova J, Sala C, Fullam E, Schneider P, McKinney JD, Brodin P, Christophe T, Waddell S, Butcher P, Albrethsen J, Rosenkrands I, Brosch R, Nandi V, Bharath S, Gaonkar S, Shandil RK, Balasubramanian V, Balganesh T, Tyagi S, Grosset J, Riccardi G, Cole ST. 2009. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324:801-804. http://dx.doi.org/10.1126/science.1171583.
12. Lechartier B, Hartkoorn RC, Cole ST. 2012. In Vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:5790-5793. http://dx.doi.org/10.1128/AAC.01476-12.
13. Makarov V, Lechartier B, Zhang M, Neres J, van der Sar AM, Raadsen SA, Hartkoorn RC, Ryabova OB, Vocat A, Decosterd LA, Widmer N, Buclin T, Bitter W, Andries K, Pojer F, Dyson PJ, Cole ST. 2014. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Mol Med 6:372-383. http://dx.doi.org/10.1002/emmm.201303575.
14. Zhang M, Sala C, Hartkoorn RC, Dhar N, Mendoza-Losana A, Cole ST. 2012. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother 56:5782-5789. http://dx.doi.org/10.1128/AAC.01125-12.
15. Tasneen R, Li S, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. 2011. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 55:5485-5492. http://dx.doi.org/10.1128/AAC.05293-11.
16. Lechartier B, Rybniker J, Zumla A, Cole S. 2014. Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med 6:158-168. http://dx.doi.org/10.1002/emmm.201201772.
17. Hartkoorn RC, Uplekar S, Cole ST. 2014. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:2979-2981. http://dx.doi.org/10.1128/AAC.00037-14.
18. Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong B, Koul A, Beerse B, Antwerp B. 2014. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 9:e102135. http://dx.doi.org/10.1371/journal.pone.0102135.
19. Debnath J, Siricilla S, Wan B, Crick DC, Lenaerts AJ, Franzblau SG, Kurosu M. 2012. Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis. J Med Chem 55:3739-3755. http://dx.doi.org/10.1021/jm201608g.
20. Gurumurthy M, Rao M, Mukherjee T, Rao S, Boshoff H, Dick T, Berry CE, III, Manjunatha U. 2013. A novel F(420)-dependent anti-oxidant mechanism protects Mycobacterium tuberculosis against oxidative stress and bactericidal agents. Mol Microbiol 87:744-755. http://dx.doi.org/10.1111/mmi.12127.
21. Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC, Angala SK, Chatterjee D, Biswas K, Narayanasamy P, Kurosu M, Crick DC. 2009. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Mol Microbiol 72:85-97. http://dx.doi.org/10.1111/j.1365-2958.2009.06625.x.
22. Kurosu M, Begari E. 2010. Vitamin K2 in electron transport system: are enzymes involved in vitamin K2 biosynthesis promising drug targets? Molecules 15:1531-1553. http://dx.doi.org/10.3390/molecules15031531.
23. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs J, Winkler H, van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10.1126/science.1106753.
24. Gomez JE, McKinney JD. 2004. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 84:29-44. http://dx.doi.org/10.1016/j.tube.2003.08.003.
25. Zhang M, Sala C, Dhar N, Vocat A, Sambandamurthy VK, Sharma S, Marriner G, Balasubramanian V, Cole ST. 2014. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:3217-3223. http://dx.doi.org/10.1128/AAC.02410-14.
26. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim S, Nam J, Kang H, Kwon H, Oh C, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SPS, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han S, No Z, Lee J, Brodin P, Cho S, Nam K, Kim J. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19:1157-1160. http://dx.doi.org/10.1038/nm.3262.
27. Cook GM, Heikal A. 2012. Bridging the gap between a TB drug and its target. Sci Transl Med 4:150fs33. http://dx.doi.org/10.1126/scitranslmed.3004816.
28. Reddy VM, Einck L, Andries K, Nacy CA. 2010. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 54:2840-2846. http://dx.doi.org/10.1128/AAC.01601-09.
29. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Carry CE, III, Boshoff HI. 2012. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:1797-1809. http://dx.doi.org/10.1128/AAC.05708-11.
30. Li K, Schurig-Briccio LA, Feng X, Upadhyay A, Pujari V, Lechartier B, Fontes FL, Yang H, Rao G, Zhu W, Gulati A, No JH, Cintra G, Bogue S, Liu Y, Molohon K, Orlean P, Mitchell DA, Freitas-Junior L, Ren F, Sun H, Jiang T, Li Y, Guo R, Cole ST, Gennis RB, Crick DC, Oldfield E. 2014. Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 57:3126-3139. http://dx.doi.org/10.1021/jm500131s.
31. Cardona P, Ruiz-Manzano J. 2004. On the nature of Mycobacterium tuberculosis-latent bacilli. Eur Respir J 24:1044-1051. http://dx.doi.org/10.1183/09031936.04.00072604.
32. Mack U, Migliori GB, Sester M, Rieder HL, Ehlers S, Goletti D, Bossink A, Magdorf K, Holscher C, Kampmann B, Arend SM, Detjen A, Bothamley G, Zellweger JP, Milburn H, Diel R, Ravn P, Cobelens F, Cardona PJ, Kan B, Solovic I, Duarte R, Cirillo DM. 2009. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 33:956-973. http://dx.doi.org/10.1183/09031936.00120908.
33. Neres J, Pojer F, Molteni E, Chiarelli LR, Dhar N, Boy-Rottger S, Buroni S, Fullam E, Degiacomi G, Lucarelli AP, Read RJ, Zanoni G, Edmondson DE, de Rossi E, Pasca MR, McKinney JD, Dyson PJ, Riccardi G, Mattevi A, Cole ST, Binda C. 2012. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med 4:150ra121. http://dx.doi.org/10.1126/scitranslmed.3004395.
34. Wolucka BA. 2008. Biosynthesis of D-arabinose in mycobacteria-a novel bacterial pathway with implications for antimycobacterial therapy. FEBS J 275:2691-2711. http://dx.doi.org/10.1111/j.1742-4658.2008.06395.x.